tetano
Editor, Senior Moderator
J Biomol Struct Dyn
. 2020 May 25;1-14.
doi: 10.1080/07391102.2020.1772885. Online ahead of print.
Repurposing Approved Drugs as Inhibitors of SARS-CoV-2 S-protein From Molecular Modeling and Virtual Screening
Osmair Vital de Oliveira[SUP] 1 [/SUP], Gerd B Rocha[SUP] 2 [/SUP], Andrew S Paluch[SUP] 3 [/SUP], Luciano T Costa[SUP] 4 [/SUP]
Affiliations
Abstract
Herein, molecular modeling techniques were used with the main goal to obtain candidates from a drug database as potential targets to be used against SARS-CoV-2. This novel coronavirus, responsible by the COVID-19 outbreak since the end of 2019, became a challenge since there is not vaccine for this disease. The first step in this investigation was to solvate the isolated S-protein in water for molecular dynamics (MD) simulation, being observed a transition from "up" to "down" conformation of receptor-binding domain (RBD) of the S-protein with angle of 54.3 and 43.0 degrees, respectively. The RBD region was more exposed to the solvent and to the possible drugs due to its enhanced surface area. From the equilibrated MD structure, virtual screening by docking calculations were performed using a library contained 9091 FDA approved drugs. Among them, 24 best-scored ligands (14 traditional herbal isolate and 10 approved drugs) with the binding energy below -8.1 kcal/mol were selected as potential candidates to inhibit the SARS-CoV-2 S-protein, preventing the human cell infection and their replication. For instance, the ivermectin drug (present in our list of promise candidates) was recently used successful to control viral replication in vitro. MD simulations were performed for the three best ligands@S-protein complexes and the binding energies were calculated using the MM/PBSA approach. Overall, it is highlighted an important strategy, some key residues, and chemical groups which may be considered on clinical trials for COVID-19 outbreak.
Keywords: COVID-19; SARS-CoV-2 virus; Spike protein; drug design; molecular modeling.
. 2020 May 25;1-14.
doi: 10.1080/07391102.2020.1772885. Online ahead of print.
Repurposing Approved Drugs as Inhibitors of SARS-CoV-2 S-protein From Molecular Modeling and Virtual Screening
Osmair Vital de Oliveira[SUP] 1 [/SUP], Gerd B Rocha[SUP] 2 [/SUP], Andrew S Paluch[SUP] 3 [/SUP], Luciano T Costa[SUP] 4 [/SUP]
Affiliations
- PMID: 32448085
- DOI: 10.1080/07391102.2020.1772885
Abstract
Herein, molecular modeling techniques were used with the main goal to obtain candidates from a drug database as potential targets to be used against SARS-CoV-2. This novel coronavirus, responsible by the COVID-19 outbreak since the end of 2019, became a challenge since there is not vaccine for this disease. The first step in this investigation was to solvate the isolated S-protein in water for molecular dynamics (MD) simulation, being observed a transition from "up" to "down" conformation of receptor-binding domain (RBD) of the S-protein with angle of 54.3 and 43.0 degrees, respectively. The RBD region was more exposed to the solvent and to the possible drugs due to its enhanced surface area. From the equilibrated MD structure, virtual screening by docking calculations were performed using a library contained 9091 FDA approved drugs. Among them, 24 best-scored ligands (14 traditional herbal isolate and 10 approved drugs) with the binding energy below -8.1 kcal/mol were selected as potential candidates to inhibit the SARS-CoV-2 S-protein, preventing the human cell infection and their replication. For instance, the ivermectin drug (present in our list of promise candidates) was recently used successful to control viral replication in vitro. MD simulations were performed for the three best ligands@S-protein complexes and the binding energies were calculated using the MM/PBSA approach. Overall, it is highlighted an important strategy, some key residues, and chemical groups which may be considered on clinical trials for COVID-19 outbreak.
Keywords: COVID-19; SARS-CoV-2 virus; Spike protein; drug design; molecular modeling.